Health data intelligence: Advancing patient research and care using genetic insights
Data-driven medical information and genetic insights are vital to advancing scientific innovation, supporting research, and improving health outcomes. As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements.
In this webinar, attendees will hear from medical, scientific and technology leaders at Myriad Genetics and learn about:
The health data intelligence ecosystem and integration of data into open-source standards and extensible platforms
How Myriad is working in partnership with DNAnexus to improve treatment decisions and patient care through data-driven genetic insights
Myriad’s new Precise™ Treatment Registry, which creates an open environment for improving and advancing cancer care by leveraging the insights of combined genomic and de-identified clinical data
The role data plays in research and development of new products and/or product enhancements.
Kevin R. Haas, Chief Technology Officer, joined Myriad Genetics in May 2013. Today he is responsible for building Myriad's precision medicine platform to improve the patient/provider experience through digital engagement, harnessing genetic data, and powering breakthrough products to serve millions of customers. Dr. Haas received a B.S. from University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics from single molecule fluoresce. He has co-authored 16 peer reviewed publications and ten patent applications.
Dr. Thomas (T.J.) Slavin is Chief Medical Officer of Myriad Genetics and was formerly Senior Vice President of Medical Affairs for Oncology at Myriad. He is a physician-scientist, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. Focused on expanding genetics education for cancer care providers, Dr. Slavin has helped shape both ASCO University as well as City of Hope’s hereditary genomics training program. He is a well-respected researcher in the field of medical genetics, publishing over 75 journal articles collectively evaluating genomic data from over 500,000 patients, multiple book chapters, and providing numerous presentations at national and international medical meetings.
Dale Muzzey is chief scientific officer of Myriad Genetics. Previously, he was senior vice president of R&D. Dr. Muzzey received a B.A. in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.
